The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2025

Filed:

Jul. 09, 2021
Applicant:

Precigen, Inc., Germantown, MD (US);

Inventors:

Helen Sabzevari, Germantown, MD (US);

Simon Metenou, Germantown, MD (US);

Chang Hung Chen, Germantown, MD (US);

Rutul Shah, Germantown, MD (US);

Assignee:

Precigen, Inc., Germantown, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 38/179 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); A61K 39/001102 (2018.08); A61K 39/001112 (2018.08); A61K 39/001129 (2018.08); A61K 39/00117 (2018.08); A61K 39/001195 (2018.08); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61K 39/464411 (2023.05); A61K 39/464412 (2023.05); A61K 39/464417 (2023.05); A61K 39/464429 (2023.05); A61K 39/464434 (2023.05); A61K 39/46447 (2023.05); A61K 39/464495 (2023.05); C07K 14/71 (2013.01); C07K 16/2818 (2013.01); C07K 16/2857 (2013.01); C07K 16/2863 (2013.01); C07K 16/2866 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 16/2884 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C07K 16/3092 (2013.01); A61K 2239/50 (2023.05); A61K 2239/54 (2023.05); A61K 2239/55 (2023.05); A61K 2239/59 (2023.05);
Abstract

A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.


Find Patent Forward Citations

Loading…